Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 52

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 52
---
 insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; |

| ● | our contractors and investigators may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;                                                                 |
| ● | we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a lack of clinical response or a determination that participants are being exposed to unacceptable health risks; |
| ● | regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including non-compliance with regulatory requirements;                            |
| ● | the cost of clinical trials of our drug candidates may be greater than we anticipate;                                                                                                                                        |
| ● | the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and                                                           |
| ● | our drug candidates may cause adverse events, have undesirable side effects or other unexpected characteristics, causing us, our investigators, or regulators to suspend or terminate the trials.                            |

<div align='center'>23</div>

If we are required to conduct
additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully
complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only
modestly positive or if they raise safety concerns, we may:

| ● | be delayed in obtaining regulatory approval for our drug candidates; |
| ● | not obtain regulatory approval at all;                               |

| ● | obtain approval for indications that are not as broad as intended;       |
| ● | have a drug removed from the market after obtaining regulatory approval; |
| ● | be subject to additional post-marketing testing requirements;            |
| ● | be subject to restrictions on how a drug is distributed or used; or      |
| ● | be unable to obtain reimbursement for use of a drug.                     |

Delays in testing or approvals
may result in increases in our drug development costs. We do not know whether any clinical trials will begin as planned, will need to
be restructured, or will be completed on schedule, or at all. Clinical trials may produce negative or inconclusive results. Moreover,
these trials may be delayed or proceed less quickly than intended. Delays in completing our clinical trials will increase our costs, slow
down our drug candidate development and approval process, and jeopardize our ability to commence